- Humanetics Corporation

Medtronic, Inc.

University of Pennsylvania

Other

New Hope Research Foundation, Inc.

University System of Maryland

Michael D Kaytor

William Frederick Kaemmerer

John C Dykstra

David Egberg

John L Zenk

Adam J Harvey

Keith Cengel

Eric Stanton Diffenderfer

John G Keimel

Erica M TenBroek

Zeljko Vujaskovic

Isabel Lauren Jackson

Geoffrey E Schroeder

Isabel L Jackson

Eric N Burright

Janelle L Blum

Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.

Sensitizing cells to proton radiation

Materials and methods for reducing, preventing, or mitigating the effects of exposure to ionizing radiation are provided herein. In general, the methods can include administering a nanoparticulate genistein composition to a subject identified as having been exposed or at risk of being exposed to ionizing radiation, such as proton radiation.

Protecting tissue and mitigating injury from radiation-induced ionizing events

The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.

Suspension compositions of physiologically active phenolic compounds and methods of making and using the same

Mitigation of long and short-term detrimental effects of exposure to low dose ionizing radiation by administration of genistein in the form of a nanosuspension to a mammal in an amount effective for achieving genistein serum levels of between 1-5 &#x3bc;M in the mammal throughout a time period from exposure to the ionizing radiation to twelve hours after exposure to the ionizing radiation.

Method of mitigating long and short term detrimental effects of exposure to low dose ionizing radiation by administration of genistein

Embodiments herein include polynucleotides, vectors and methods for the insertion and expression of transgenes. In an embodiment, a polynucleotide is included. The polynucleotide can include a JeT promoter or variant thereof, an intron sequence less than 400 bases in length, and a polynucleotide sequence encoding a polypeptide or protein operatively linked to the promoter. In an embodiment, a recombinant vector is included. The recombinant vector can include a JeT promoter or variant thereof, an intron sequence less than 400 bases in length, and a polynucleotide sequence encoding a polypeptide or protein operatively linked to the promoter. Other embodiments are also included herein.

Polynucleotides, vectors and methods for insertion and expression of transgenes

Mitigation of long term detrimental effects of exposure to medical imaging ionizing radiation by administration of an amount of genistein in the form of a nanosuspension to someone effective for achieving genistein serum levels of between 1-5 &#x3bc;M in the mammal throughout a time period from exposure to medical imaging ionizing radiation to twelve hours after exposure to medical imaging ionizing radiation.

Method of mitigating long term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein

A method for mitigating erectile dysfunction as an adverse side effect of radiation therapy for prostate cancer, comprising administration of a therapeutic dosage of genistein to a patient diagnosed with prostate cancer throughout only a primary administration period that commences a defined period of up to two weeks prior to commencement of radiation therapy for prostate cancer and extends beyond conclusion of the radiation therapy.

Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy

Mitigation of long and short-term detrimental effects of exposure to medical imaging ionizing radiation by administration of an effective amount of genistein in the form of a nanosuspension to someone within forty eight hours prior to and/or within twelve hours after exposure to medical imaging ionizing radiation.

Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein

The present invention provides devices, small interfering RNAs, and methods for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance capable of inhibiting production of at least one neurodegenerative protein. The present invention also provides valuable small interfering RNA vectors, systems, and methods for treating Huntington's disease in vivo without impairment of cell endoplasmic reticulum, spontaneous motor activity, or locomotor activity of a patient.

Growing community of inventors

Maplewood, MN, United States of America

Michael D Kaytor